文献速递肝胆胰外科围术期管理与 ERAS

胰腺癌动脉切除联合胰腺切除术:118例单中心安全性与结局

Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience With 118 Patients.
PubMed 文献 · Ann Surg · 2020-01-01

该单中心回顾性研究纳入1990年至2017年118例因局部进展期胰腺导管腺癌行联合动脉切除的胰腺切除术患者,总体死亡率为5.1%、并发症率为41.5%,中位总生存期为13.70个月;多因素分析显示R0切除与静脉侵犯是独立预后因素。

要点

  • 在专科中心,联合动脉切除的胰腺切除术死亡率为5.1%、并发症率为41.5%。
  • R0切除率为52.4%,病理静脉壁侵犯率为74.2%,动脉壁侵犯率为58%。
  • R0切除(HR 0.60)与静脉侵犯(HR 1.67)为独立预后因素。

核心结论

  • 在专科中心,针对局部进展期胰腺导管腺癌行联合动脉切除的胰腺切除术可安全实施,死亡率和并发症率有限。
  • 阴性切缘及无相关静脉侵犯可能预示较好的长期结局。

研究设计与样本

  • 单中心回顾性研究,前瞻性维护数据库,纳入1990年1月至2017年11月间接受联合动脉切除的胰腺切除术患者118例。
  • 手术方式包括胰十二指肠切除术51例、全胰腺切除术18例、远端胰脾切除术49例。
  • 切除动脉段包括腹腔干50例、肝动脉29例、肠系膜上动脉35例及其他段4例。

主要发现

  • 总体死亡率为5.1%,并发症率为41.5%。
  • 84例(75.4%)接受新辅助化疗,105例(89%)同期行静脉切除,101例(85.5%)行动脉重建。
  • R0切除率为52.4%,病理静脉壁侵犯率为74.2%,动脉壁侵犯率为58%。
  • 1年、3年、5年总生存率分别为59%、13%、11.8%;切除后中位总生存期为13.70个月(95%CI:11-18.5个月)。
  • 多因素分析显示,R0切除(HR:0.60;95%CI:0.38-0.96;P=0.01)和静脉侵犯(HR:1.67;95%CI:1.01-2.63;P=0.04)为独立预后因素。

临床怎么用

  • 在专科中心,对严格选择的局部进展期胰腺导管腺癌患者可考虑联合动脉切除的胰腺切除术,需充分评估手术风险。
  • R0切除与无静脉侵犯提示较好长期结局,术中应追求阴性切缘并评估静脉侵犯情况。

局限性

  • 单中心回顾性研究,样本来自单一机构,结果外推需谨慎。
  • 研究跨越1990年至2017年,治疗策略和围术期管理可能随时间变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assesses the safety and outcomes of the largest cohort of pancreatectomy with arterial resection (P-AR). BACKGROUND: A high postoperative mortality rate and uncertain oncologic benefits have limited the use of P-AR for locally advanced pancreatic adenocarcinoma. METHODS: We retrospectively reviewed a prospectively maintained database of patients who underwent P-AR between January 1990 and November 2017. Univariate and multivariate Cox analyses were used to assess prognostic factors for survival. RESULTS: There were 118 consecutive resections (51 pancreaticoduodenectomies, 18 total pancreatectomies, and 49 distal splenopancreatectomies). Resected arterial segments included the coeliac trunk (50), hepatic artery (29), superior mesenteric artery (35), and other segments (4). The overall mortality and morbidity were 5.1% and 41.5%, respectively. There were 84 (75.4%) patients who received neoadjuvant chemotherapy, 105 (89%) simultaneous venous resections, and 101 (85.5%) arterial reconstructions. The rates of R0 resection and pathologic invasion of venous and arterial walls were 52.4%, 74.2%, and 58%, respectively. The overall survival was 59%, 13%, and 11.8% at 1, 3, and 5 years, respectively. The median overall survival after resection was 13.70 months (CI 95%:11-18.5 mo). In multivariate analysis, R0 resection (HR: 0.60; 95% CI: 0.38-0.96; P = 0.01) and venous invasion (HR: 1.67; 95% CI: 1.01-2.63; P = 0.04) were independent prognostic factors. CONCLUSION: In a specialized setting, P-AR for locally advanced pancreatic adenocarcinoma can be performed safely with limited mortality and morbidity. Negative resection margin and the absence of associated venous invasion might predict favorable long-term outcomes.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Bachellier P, Addeo P, Faitot F, et al. Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience With 118 Patients. Ann Surg. 2020. PMID: 30188399. doi:10.1097/SLA.0000000000003010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。